Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Pharma-Bio Serv (PBSV) over the last 15 years, with Q4 2025 value amounting to -$102.0.

  • Pharma-Bio Serv's Income towards Parent Company fell 10063.31% to -$102.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$110021.0, marking a year-over-year increase of 8585.16%. This contributed to the annual value of -$100463.0 for FY2025, which is 8708.07% up from last year.
  • Per Pharma-Bio Serv's latest filing, its Income towards Parent Company stood at -$102.0 for Q4 2025, which was down 10063.31% from -$213808.0 recorded in Q3 2025.
  • Over the past 5 years, Pharma-Bio Serv's Income towards Parent Company peaked at $2.3 million during Q3 2021, and registered a low of -$4.9 million during Q4 2021.
  • In the last 5 years, Pharma-Bio Serv's Income towards Parent Company had a median value of $134366.0 in 2022 and averaged -$33000.8.
  • Examining YoY changes over the last 5 years, Pharma-Bio Serv's Income towards Parent Company showed a top increase of 22872.01% in 2021 and a maximum decrease of 347565.8% in 2021.
  • Pharma-Bio Serv's Income towards Parent Company (Quarter) stood at -$4.9 million in 2021, then soared by 103.56% to $173379.0 in 2022, then tumbled by 127.19% to -$47148.0 in 2023, then soared by 134.17% to $16111.0 in 2024, then tumbled by 100.63% to -$102.0 in 2025.
  • Its Income towards Parent Company was -$102.0 in Q4 2025, compared to -$213808.0 in Q3 2025 and $95353.0 in Q2 2025.